Kodiak Sciences has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were mentioned in the filing, although the offering is valued up to $100 million, but this number is usually just a placeholder. The company intends to list its shares on the Nasdaq under the symbol KOD.
The underwriters for the offering are Morgan Stanley, Merrill Lynch, Barclays and Chardan.
This is a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Its most advanced product candidate is KSI-301, a biologic therapy built with its antibody biopolymer conjugate (ABC) platform, which is designed to maintain potent and effective drug levels in ocular tissues.
Management believes that KSI-301, if approved, has the potential to become an important anti-VEGF therapy in wet age-related macular degeneration (wet AMD), and diabetic retinopathy (DR). KSI-301 and the ABC Platform were developed at Kodiak, and the firm owns worldwide rights to those assets, including composition of matter patent protection for KSI-301.
Kodiak has applied its ABC Platform to develop additional product candidates beyond KSI-301, including KSI-501, its bispecific anti-IL-6/VEGF bioconjugate. Management intends to progress these and other product candidates to address high-prevalence ophthalmic diseases.
The company detailed its plans for the net proceeds in the filing as follows:
- To advance KSI-301 through enrollment of the Phase 2 clinical trial in the U.S., EU and rest of the world in patients with wet AMD and to expand the scope of our Phase 1 clinical trial for KSI-301 through completion of a Phase 1b clinical trial;
- To advance KSI-301 into Phase 2 clinical trials in China for wet AMD and DME/DR;
- To advance KSI-301 into the Phase 2 clinical trial in the U.S., EU and rest of the world in patients with DME/DR;
- Towards research and development of our pipeline including KSI-501, and to initiate additional clinical studies in ophthalmology; and
- The remainder for working capital and other general corporate purposes.
Essential Tips for Investing (Sponsored)
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
